CRLF3 (cytokine receptor-like factor 3) gene is mapped to human chromosome 17q11.2 and is found to be frequently deleted in patients with Neurofibromatosis type 1 (NF1) microdeletions in the neurofibromin locus. It is also called as p48.2 based on its predicted molar mass and it encodes a 438aa intracellular protein. It contains a typical fibronectin type III (FNIII) domain. A palindromic Arg-Gly-Asp (RGD) repeat and a putative Trp-Ser-X-Trp-Ser (WSXWS) motif are located at the C-terminus of this domain. Its expression is found to be increased in lung cancer and leukemia cells. It is distributed in both cytoplasm and cell membrane in mammalian cells.
Synonyms: Anti-CREME-9; Anti-Cytokine receptor-like factor 3; Anti-Cytokine receptor-like molecule 9; Anti-Cytokine receptor-related protein 4; Anti-Type I cytokine receptor-like factor p48
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: CRLF3 (cytokine receptor-like factor 3) gene encodes a cytokine receptor-like factor that may be involved in the negative regulation of cell cycle progression at the G0/G1 phase. This inhibits the cells from entering the S phase.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC